- |||||||||| paclitaxel / generics
Biomarker, Clinical, Journal: miR-195 Potentiates the Efficacy of Microtubule-Targeting Agents in Non-Small Cell Lung Cancer. (Pubmed Central) - Aug 1, 2019 Additionally, we demonstrate that miR-195 targets checkpoint kinase 1 (CHEK1) to regulate the response of NSCLC cells to MTAs, that over-expression of CHEK1 contributes to resistance to MTAs and that knock-down of CHEK1 synergizes with MTAs to repress cell growth. Our results highlight the importance of miR-195 in regulating the response of NSCLC cells to MTAs and underline the potential application of miR-195 as a biomarker for response to MTAs, and as a therapeutic adjuvant to MTA treatment.
- |||||||||| Halaven (eribulin mesylate) / Eisai
Enrollment open, Trial initiation date, Metastases: Loreline Study: Characterization of Long Responders Under Eribuline (clinicaltrials.gov) - Jul 24, 2019 P=N/A, N=200, Recruiting, Our results highlight the importance of miR-195 in regulating the response of NSCLC cells to MTAs and underline the potential application of miR-195 as a biomarker for response to MTAs, and as a therapeutic adjuvant to MTA treatment. Not yet recruiting --> Recruiting | Initiation date: Jan 2019 --> Jun 2019
- |||||||||| Tarceva (erlotinib) / Astellas, Roche
Journal: Tyrosine Kinase Inhibitors Imatinib and Erlotinib Increase Apoptosis of Antimitotic Drug-resistant KBV20C Cells Without Inhibiting P-gp. (Pubmed Central) - Jul 11, 2019 These findings provide important information regarding the sensitization of drug-resistant cells and indicate that loratadine may be used in patients with potentially resistant cancer without any toxic effects from P-gp inhibition. These findings provide valuable information regarding the sensitizing of drug-resistant cells and indicate that imatinib and erlotinib may be used in patients with potentially resistant cancer without any toxic effects from P-gp inhibition.
- |||||||||| paclitaxel trevatide (ANG1005) / Angiochem
Trial completion date, Trial initiation date, Trial primary completion date: ANGLeD: ANG1005 in Leptomeningeal Disease From Breast Cancer (clinicaltrials.gov) - Jul 8, 2019 P3, N=150, Not yet recruiting, These findings provide valuable information regarding the sensitizing of drug-resistant cells and indicate that imatinib and erlotinib may be used in patients with potentially resistant cancer without any toxic effects from P-gp inhibition. Trial completion date: Dec 2021 --> Mar 2022 | Initiation date: Sep 2019 --> Dec 2019 | Trial primary completion date: Mar 2021 --> Jun 2021
- |||||||||| Halaven (eribulin mesylate) / Eisai, Tecentriq (atezolizumab) / Roche
Trial suspension, Combination therapy, PD(L)-1 Biomarker, IO biomarker, Metastases: Atezolizumab With or Without Eribulin Mesylate in Treating Patients With Recurrent Locally Advanced or Metastatic Urothelial Cancer (clinicaltrials.gov) - Jul 2, 2019 P2, N=78, Suspended, Active, not recruiting --> Recruiting Recruiting --> Suspended
- |||||||||| Biomarker, Review, Journal, BRCA Biomarker, PARP Biomarker, PD(L)-1 Biomarker, IO Biomarker: How I treat metastatic triple-negative breast cancer. (Pubmed Central) - Jun 25, 2019
In patients with a high disease burden or who are very symptomatic, combinations such as anthracyclines plus cyclophosphamide or platins with taxanes are valid options...For patients who progressed to taxanes and anthracyclines, or who present contraindications to these agents, fluorouracil/capecitabine, eribulin, gemcitabine, cisplatin/carboplatin, vinorelbine and ixabepilone are alternatives. The treatment of TNBC is constantly evolving, and the inclusion of patients in ongoing trials evaluating new targeted agents, immunotherapy and predictive biomarkers should be encouraged, in an attempt to improve metastatic TNBC treatment outcomes.
- |||||||||| Talzenna (talazoparib) / Pfizer
Trial completion date, BRCA Biomarker, PARP Biomarker, Metastases: A Study Evaluating Talazoparib (BMN 673), a PARP Inhibitor, in Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (EMBRACA Study) (clinicaltrials.gov) - Jun 25, 2019 P3, N=431, Active, not recruiting, The treatment of TNBC is constantly evolving, and the inclusion of patients in ongoing trials evaluating new targeted agents, immunotherapy and predictive biomarkers should be encouraged, in an attempt to improve metastatic TNBC treatment outcomes. Trial completion date: Sep 2019 --> Sep 2020
- |||||||||| Avastin (bevacizumab) / Roche
Clinical, Journal: A Case of a Breast Cancer Patient with Cardiac Metastasis (Pubmed Central) - Jun 15, 2019 The cardiac metastasis did not progress during chemotherapy with eribulin. There was no sign of heart failure or arrhythmia during the treatment.
- |||||||||| Halaven (eribulin mesylate) / Eisai, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Clinical, Journal, IO Biomarker: Selectively high efficacy of eribulin against high-grade invasive recurrent and/or metastatic squamous cell carcinoma of the head and neck. (Pubmed Central) - Jun 13, 2019 ...Over the past decade, a major development in the first-line treatment of R/M SCCHN was the introduction of cetuximab in combination with platinum plus 5-fluorouracil chemotherapy...In the present study, the effects of eribulin, paclitaxel and vinblastine were investigated in R/M SCCHN (OLC-01 and OSC-19) and locally advanced SCCHN (OSC-20) cells...In conclusion, the results highlight the existence of invasive-type heterogeneity in R/M SCCHN with respect to eribulin sensitivity. Eribulin is already an approved clinical agent; therefore, the continued investigation of its preclinical antitumor attributes may contribute significantly to the future process of identifying novel uses of eribulin against R/M SCCHN.
- |||||||||| Halaven (eribulin mesylate) / Eisai
Enrollment change: HAL03T: A Study on Safety and Efficacy in Patients With Soft Tissue Sarcomas (clinicaltrials.gov) - Jun 13, 2019 P=N/A, N=256, Completed, Eribulin is already an approved clinical agent; therefore, the continued investigation of its preclinical antitumor attributes may contribute significantly to the future process of identifying novel uses of eribulin against R/M SCCHN. N=160 --> 256
- |||||||||| Halaven (eribulin mesylate) / Eisai
Trial completion date, Trial primary completion date: Carboplatin and Eribulin Mesylate in Triple Negative Breast Cancer Patients (clinicaltrials.gov) - Jun 7, 2019 P2, N=30, Active, not recruiting, Our findings indicate that, with respect to CIPN, eribulin is well-tolerated, as approximately one-quarter of patients developed CIPN, most cases were grade 1 or 2, and the majority of patients continued eribulin after CIPN onset. Trial completion date: Jun 2019 --> Jun 2021 | Trial primary completion date: Jun 2018 --> Jun 2020
- |||||||||| Keytruda (pembrolizumab) / Merck (MSD), Halaven (eribulin mesylate) / Eisai
Enrollment open: A Phase II Study of Eribulin and Pembrolizumab in Soft Tissue Sarcomas (clinicaltrials.gov) - Jun 6, 2019 P2, N=57, Recruiting, Trial completion date: Jun 2019 --> Jun 2021 | Trial primary completion date: Jun 2018 --> Jun 2020 Not yet recruiting --> Recruiting
- |||||||||| Halaven (eribulin mesylate) / Eisai
Clinical, Journal: The safety of eribulin for the treatment of metastatic breast cancer. (Pubmed Central) - May 30, 2019 The use of eribulin in combination with other therapies is beginning to be explored because its manageable safety profile makes it an ideal combination-treatment partner. Emerging eribulin combination-treatment data suggest a manageable toxicity profile, and eribulin is set to be a key drug for the treatment of MBC in the future.
- |||||||||| paclitaxel / generics, doxorubicin hydrochloride / generics
Clinical, Journal: Jekyll and Hyde of chemotherapy treatment: method for patient specific dosing of chemotherapy medications. (Pubmed Central) - May 29, 2019 A new method to dose chemotherapy based on a patients albumin will maintain the same effective free drug levels as in patients with normal albumin. This can reduce the severity of chemotherapy side-effects and may: ensure better outcomes for patients since it allows them to complete their course of chemotherapy without interruption, decrease the cost and complications associated with severe side-effects, and will allow for enhanced treatment options.
- |||||||||| Halaven (eribulin mesylate) / Eisai, Imfinzi (durvalumab) / AstraZeneca
Trial primary completion date, Combination therapy, Metastases: Durvalumab and Eribulin in Her2-negative Metastatic Breast Cancer and Recurrent Ovarian Cancer (clinicaltrials.gov) - May 28, 2019 P1, N=9, Active, not recruiting, This can reduce the severity of chemotherapy side-effects and may: ensure better outcomes for patients since it allows them to complete their course of chemotherapy without interruption, decrease the cost and complications associated with severe side-effects, and will allow for enhanced treatment options. Trial primary completion date: May 2019 --> May 2020
|